Valuation: Infinity Pharmaceuticals, Inc.

Market Cap 2L 2L 2L 2L 3L 2.15Cr 3L 22.23L 9L 1.13Cr 9L 8L 3.6Cr P/E 2021
-4.25x
P/E 2022 -1.11x
Enterprise Value 1.13Cr 1.01Cr 92.42L 83.94L 1.58Cr 106.68Cr 1.62Cr 11Cr 4.44Cr 56Cr 4.23Cr 4.14Cr 178.47Cr EV / Sales 2021
91.8x
EV / Sales 2022 23.4x
Free-Float
100%
Yield 2021 *
-
Yield 2022 -
1 week 0
Extreme 1.0E-6
0
1 month 0
Extreme 1.0E-6
0
Current year 0
Extreme 1.0E-6
0
1 year 0
Extreme 1.0E-6
0
3 years 0
Extreme 1.0E-6
0.02
5 years 0
Extreme 1.0E-6
2.81
10 years 0
Extreme 1.0E-6
5.98
Date Insider Type Main position Quantity % Market Cap. Importance
08/09/23 Exercice

Chief Executive Officer

19,46,462 2.1446%
02/08/22 Exercice

Chief Technology Officer

1,14,994 0.1290%
16/06/22 Free

Director

45,000 0.0505%
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--%-.--%-99.97% 90
-1.28%-0.48%+19.26%+39.58% 9.33TCr
-1.26%+3.06%+18.31%+58.27% 7.4TCr
-0.80%+2.58%+12.61%+40.10% 4.67TCr
+0.54%+12.72%+17.57%+64.29% 2.83TCr
-0.45%+1.25%+4.15%+56.70% 2TCr
-0.43%-5.79%+41.25%+90.69% 1.55TCr
-0.40%+6.89%+23.70%+28.61% 1.01TCr
+0.67%+0.59%+1.68%+44.10% 995.67Cr
-1.70%+2.69%+8.46%+21.61% 612.41Cr
Average -0.33%+2.15%+14.70%+34.40% 3.04TCr
Weighted average by Cap. -0.28%+1.94%+17.34%+49.67%

Financials

2021 2022
Net sales 18.58L 16.6L 15.25L 13.85L 26.01L 18Cr 26.66L 1.82Cr 73.22L 9.29Cr 69.74L 68.25L 29Cr 25.93L 23.17L 21.28L 19.33L 36.29L 25Cr 37.2L 2.54Cr 1.02Cr 13Cr 97.33L 95.25L 41Cr
Net income -4.53Cr -4.04Cr -3.71Cr -3.37Cr -6.34Cr -428.76Cr -6.49Cr -44Cr -18Cr -226.3Cr -17Cr -17Cr -717.27Cr -4.44Cr -3.96Cr -3.64Cr -3.31Cr -6.21Cr -420.3Cr -6.37Cr -43Cr -17Cr -221.83Cr -17Cr -16Cr -703.12Cr
Net Debt -2.97Cr -2.65Cr -2.43Cr -2.21Cr -4.15Cr -281.02Cr -4.26Cr -29Cr -12Cr -148.32Cr -11Cr -11Cr -470.12Cr 1.1Cr 98.59L 90.56L 82.24L 1.54Cr 104.53Cr 1.58Cr 11Cr 4.35Cr 55Cr 4.14Cr 4.05Cr 174.87Cr
Logo Infinity Pharmaceuticals, Inc.
Infinity Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that is focused on developing medicines for people with cancer. The Company is focused on advancing eganelisib, also known as IPI-549, an orally administered, clinical-stage, immuno-oncology product candidate that reprograms macrophages through selective inhibition of the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma). Its eganelisib clinical development program includes MAcrophage Reprogramming in Immuno-Oncology-3 (MARIO-3), MARIO-275 and MARIO-1. MARIO-3 is a multi-arm Phase II study designed to evaluate eganelisib in the front-line treatment for both metastatic triple-negative breast cancer (TNBC), and renal cell carcinoma (RCC). MARIO-275 is its global, randomized, placebo-controlled Phase II study evaluating the effect of adding eganelisib to nivolumab, also known as Opdivo, in checkpoint-naive advanced urothelial cancer (UC). MARIO-1 is in the Phase I/Ib clinical study.
Employees
30
Date Price Change Volume
  1. Stock Market
  2. Stocks
  3. INFI.Q Stock